Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sotrovimab PK/PD in Pediatric COVID-19
NCT05124210Phase 2Terminated
- Sponsor
- GSK
- Start
- Dec 2021
- Primary completion
- Jun 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label trial of sotrovimab in coronavirus disease 2019 (COVID-19) (2 cohorts), sponsored by GSK. Primary endpoints: Body Weight-Adjusted Serum Clearance (CL) of Sotrovimab at Week 12, Maximum Observed Concentration (Cmax) at Week 12 and 6 more. Started Dec 2021; status: terminated.
02
Drugs
sotrovimab
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05124210.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05124210.